StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1332.HK$0.12+2.56%
Fair $0.12+0.0%

1332.HK

Touyun Biotech Group Limited

Consumer Cyclical / Packaging & ContainersHKSE

$0.12

+0.00 (+2.56%)

Fairly Valued+0.0%Fair Value $0.12Fund rank 26/100 · Data gapFallback financials|
SA 30/D
F-Score: 5/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-32.6M · quality 46.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 13/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

30/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. Revenue has declined for 3 consecutive years ROE is -52.4%, below the 5% threshold
Thesis & Journal · 1332.HKLocal privado en este navegador · Touyun Biotech Group Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$337M

P/E

12.6x

↓

EV/EBITDA

8.1x

↓

ROE

-52.4%

↓

Gross Margin

1084.2%

↑

Debt/Equity

-8.09

↓
52-Week Range$0
$0$1

TradingView lightweight chart

1332.HK price, volumen y niveles de valoración

Último $0.117Periodo -20.5%
Fair value: $0.120

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

654.9%

FCF / Net income

-1.22x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $-5.0M · net income $26.8M · FCF $-32.6M

2022-FY → 2025-FY

Gross margin

1084.2%+1046.2% pts

Operating margin

2613.8%+2626.4% pts

Net margin

-538.3%-475.6% pts

FCF margin

654.9%+667.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$-5.0M$-5.0M$7.7M$198.6M$315.8M
Net Income$26.8M$26.8M$-88.1M$-268.9M$-198.1M
EBITDA$92.4M$92.4M$-40.0M$-228.6M$-144.4M
EPS0.010.01-0.03-0.10-0.07
Gross Margin1084.2%1084.2%-715.2%28.5%38.0%
Operating Margin2613.8%2613.8%-1683.0%-43.8%-12.6%
Net Margin-538.3%-538.3%-1149.3%-135.4%-62.7%
Balance Sheet
Debt/Equity-8.09-8.09-4.62-453.901.50
Current Ratio0.170.17———
Cash Flow
Free Cash Flow$-32.6M$-32.6M$-53.6M$-14.9M$-39.3M
Returns
ROE-52.4%-52.4%105.9%31714.5%-75.0%
Valuation
P/E12.6312.63———
EV/EBITDA8.078.07———
P/B————7.55
Growth & Yield
Revenue Growth-164.9%-164.9%-96.1%-37.1%—
EPS Growth130.3%130.3%67.2%-35.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

3.9%

fácil

EPS terminal req.

$0.01

Spread vs growth

126.4%

5Y implied EPS CAGR

6.3%

razonable

EPS terminal req.

$0.01

Spread vs growth

124.0%

10Y implied EPS CAGR

8.1%

razonable

EPS terminal req.

$0.02

Spread vs growth

122.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +30.4%

Total return

+30.4%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.03 → 0.01

Residual

+30.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+30.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.